PTEN公司
生物
癌症研究
抑癌基因
蛋白酶体
癌症
细胞凋亡
基因
线粒体
抑制器
基因座(遗传学)
细胞生物学
癌变
遗传学
PI3K/AKT/mTOR通路
作者
Jacob M. Winter,Heidi L. Fresenius,Corey Nathaniel Cunningham,Peng Wei,Heather R. Keys,Jordan A. Berg,Alex J. Bott,Tarun Yadav,Jeremy A. Ryan,Deepika Sirohi,Sheryl R. Tripp,Paige A. Barta,Neeraj Agarwal,Anthony G. Letai,David M. Sabatini,Matthew L. Wohlever,Jared P. Rutter
出处
期刊:eLife
[eLife Sciences Publications Ltd]
日期:2022-11-21
卷期号:11
被引量:24
摘要
The tumor suppressor gene PTEN is the second most commonly deleted gene in cancer. Such deletions often include portions of the chromosome 10q23 locus beyond the bounds of PTEN itself, which frequently disrupts adjacent genes. Coincidental loss of PTEN -adjacent genes might impose vulnerabilities that could either affect patient outcome basally or be exploited therapeutically. Here, we describe how the loss of ATAD1 , which is adjacent to and frequently co-deleted with PTEN , predisposes cancer cells to apoptosis triggered by proteasome dysfunction and correlates with improved survival in cancer patients. ATAD1 directly and specifically extracts the pro-apoptotic protein BIM from mitochondria to inactivate it. Cultured cells and mouse xenografts lacking ATAD1 are hypersensitive to clinically used proteasome inhibitors, which activate BIM and trigger apoptosis. This work furthers our understanding of mitochondrial protein homeostasis and could lead to new therapeutic options for the hundreds of thousands of cancer patients who have tumors with chromosome 10q23 deletion.
科研通智能强力驱动
Strongly Powered by AbleSci AI